Document is current
Any future updates will be listed below
-
Authors
Harlianto, Netanja I. https://orcid.org/0000-0001-8196-3949
de Jong, Pim A. https://orcid.org/0000-0003-4840-6854
Foppen, Wouter https://orcid.org/0000-0003-4970-8555
Bennink, Edwin https://orcid.org/0000-0002-3689-8532
Bunk, Stijn https://orcid.org/0009-0009-3020-995X
Mastbergen, Simon C. https://orcid.org/0000-0002-8825-6486
Vorselaars, Adriane D. M. https://orcid.org/0000-0003-2777-3727
Voortman, Mareye https://orcid.org/0000-0001-8215-6794
Kloppenburg, Margreet https://orcid.org/0000-0002-9294-2307
Blanco, Francisco J. https://orcid.org/0000-0001-9821-7635
Haugen, Ida K. https://orcid.org/0000-0001-7810-2216
Berenbaum, Francis https://orcid.org/0000-0001-8252-7815
Popuri, Karteek https://orcid.org/0000-0002-1729-3255
Beg, Mirza Faisal https://orcid.org/0000-0001-6706-8630
Jansen, Mylène P. https://orcid.org/0000-0003-1929-6350
-
Funding
Funding for this research was provided by:
FP7 Ideas: European Research Council (Grant Agreement no. 115770)
- License Information
-
More Information
Article History
Received: 7 October 2024
Accepted: 14 February 2025
First Online: 24 February 2025
Declarations
:
: The study was approved by the regional ethics committees and Institutional Review Boards.
: Informed consent was taken from all individual participants.
: This manuscript has not been previously archived. No part of this manuscript, including text and graphics, is copied or published elsewhere in whole or in part. Generative AI and AI-assisted technologies were not used in the preparation of this work.
: This work was not previously presented and/or submitted as conference abstract.
: PdJ; The department of Radiology of the UMC Utrecht receives research support from Philips Healthcare, outside of the submitted work. For the present study software was provided in kind by Voronoi Health Analytics. WF: research grants from NovoNordisk and Pfizer (payments to the institution), and consultancy activities for Pfizer, all outside the scope of the submitted work. MK: consulting fees from Pfizer, CHDR, Novartis, GSK, all paid to institution. Lecture fee from Novartis. Royalties from Wolters Kluwer and Springer Verlag, paid to institution. FJB: funding from Gedeon Richter Plc., Bristol-Myers Squibb International Corporation (BMSIC), Sun Pharma Global FZE, Celgene Corporation, Janssen Cilag International N.V, Janssen Research & Development, Viela Bio, Inc., Astrazeneca AB, UCB BIOSCIENCES GMBH, UCB BIOPHARMA SPRL, AbbVie Deutschland GmbH & Co.KG, Merck KGaA, Amgen, Inc., Novartis Farmacéutica, S.A., Boehringer Ingelheim España, S.A, CSL Behring, LLC, Glaxosmithkline Research & Development Limited, Pfizer Inc, Lilly S.A., Corbus Pharmaceuticals Inc., Biohope Scientific Solutions for Human Health S.L., Centrexion Therapeutics Corp., Sanofi, TEDEC-MEIJI FARMA S.A., KiniksaPharmaceuticals, Ltd. Grunenthal. IKH: Research grant (ADVANCE) from Pfizer (payment to institution) and consulting fees from Novartis, Grünenthal and GSK, outside of the submitted work. FB: Institutional grants from TRB Chemedica. Consulting fees from AstraZeneca, Grunenthal, GSK, Novartis, 4P Pharma. Honoraria for lectures from Pfizer. Travel support from Nordic Pharma. Stock owner of 4Moving Biotech. MFB: developed the software through Voronoi Health Analytics, Inc. that was used for this study. KP: developed the software through Voronoi Health Analytics, Inc. that was used for this study. NIH: no disclosures to report. EB: no disclosures to report SB: no disclosures to report SCM: no disclosures to report ADM: no disclosures to report MV: no disclosures to report MPJ: no disclosures to report.
